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Abstract
This study investigated the effects of freeze-dried cranberry powder on anti-inflammation and lipid profiles of lipopolysaccharide (LPS)-treated
rats fed an atherogenic diet for 6 weeks. Forty Sprague-Dawley male rats (6-weeks-old) were equally divided into the following five groups: 1)
normal diet group + saline (NC); 2) atherogenic diet + saline (HFC); 3) atherogenic diet + LPS (HL); 4) atherogenic diet with 5% cranberry power
+ LPS (C5); 5) atherogenic diet with 10% cranberry power + LPS (C10). LPS (0.5 mg/kg) was injected into the abdominal cavities of rats 18
hours prior to sacrifice. At the end of the experimental period, we measured serum lipid profiles as well as levels of serum C-reactive  protein
(CRP), nitric oxide (NO), and pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and IL-10 as an anti-inflammatory 
cytokine. The mean serum high density lipoprotein (HDL)-cholesterol level in C5 rats was significantly higher than that in NC and HL rats (P
< 0.05). The mean serum levels of CRP and IL-1β were significantly lower (P < 0.05) in the cranberry powder groups compared to those in HL
rats. Additionally, mean serum IL-6 levels tended to be lower in the cranberry groups than that in the HL group, whereas serum IL-10 and NO
showed 29% and 88% higher mean values in the C5 group and 49% and 24% higher in the C10 group than those in the HL group, respectively.
These results suggest that freeze-dried cranberry powder may have beneficial effects on cardiovascular diseases by modifying serum lipids and the
early inflammatory response.
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Introduction5)
Cardiovascular diseases are the leading cause of mortality. The 
major direct cause of deaths in 2008 was cardiovascular diseases 
such as ischemic heart disease, stroke or other forms of cerebr-
ovascular disease [1]. Atherosclerosis is the primary cause of 
cardiovascular disease, including coronary sclerosis and cerebr-
ovascular disease and is unequivocally an inflammatory disease 
[2,3]. In clinical studies, blood inflammatory markers such as 
C-reactive protein (CRP), tumor necrosis factor-α  (TNF-α), 
interleukin-1β  (IL-1β) and IL-6 are altered during the prog-
ression of cardiovascular diseases including coronary sclerosis 
[4,5]. Additionally, the inflammatory blood vessel response leads 
to endothelial dysfunction, which is highly relevant to blood 
vessel diseases such as atherosclerosis and hypertension [3]. 
Therefore, the blood vessel inflammatory response should be 
considered in the development of cardiovascular disease.
Cranberry (Vaccinium macrocarpon Ait.) is a fruit rich in 
polyphenols and flavonoids mainly produced in North America 
[6]. Cranberry has anti-bacteriuria and anti-pyuria [6,7], antioxi-
dant [8], anti-carcinogenic effects [9], and positive effects on 
periodontal health [10]. Furthermore, cranberry contributes to 
reducing the risk for cardiovascular diseases by decreasing low 
density lipoprotein (LDL) oxidation, inhibiting platelet aggregation, 
and suppressing blood pressure [11]. Ruel and Couillard  [12] 
suggested the importance of consuming cranberry to maintain 
health and prevent cardiovascular diseases. Neto [13] also 
reported that cranberry has the potential ability to limit the 
progression of various vascular diseases such as atherosclerosis, 
ischemic stroke, and neurodegenerative diseases through the 
anti-oxidative and inflammatory effects of the phytochemicals 
in cranberry. However, cranberry research is still inadequate and 
has focused mainly on the antioxidant properties and use for 
urinary tract infections. Only a few studies have investigated the 
effects of cranberry on cardiovascular diseases, particularly as 
they relate to the inflammatory response. Additionally, most 
studies on cranberry utilized cranberry extracts or juices. 
However, Vinson et al. [14] reported the total phenol content 
to be higher in dried or frozen cranberry products than that in 
juice. Therefore, we used freeze-dried cranberry powder to 
maximize phenolic content in the test material.
The purpose of this study was to determine the ameliorative 
effect of cranberry on cardiovascular diseases in relation to the 
inflammatory system. Therefore, we employed the idea of LPS- 
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Fig. 1. Experimental design.   normal diet (5% corn oil),   atherogenic diet 
(5% corn oil + 10% lard + 1% cholesterol + 0.5% sodium cholate),   atherogenic 
+ 5% cranberry powder diet,   atherogenic + 10% cranberry powder diet, ▲ LPS 
injection NC, normal diet control group; HFC, atherogenic diet control group; HL, 
atherogenic  diet  and  lipopolysaccharide  (LPS)  injected  control  group;  HL-C5, 
atherogenic  + 5%  cranberry  powder  diet  and  LPS  injected  group;  HL-C10, 
atherogenic  + 10%  cranberry  powder  diet  and  LPS  injected  group
Group
Ingredient NC HFC HL HL-C5 HL-C10
Casein 20 20 20 20 20
DL-methionine 0.3 0.3 0.3 0.3 0.3
Corn starch 29.0 17.5 17.5 12.5 7.5
S u c r o s e 4 04 04 04 0 4 0
Cellulose 1.0 1.0 1.0 1.0 1.0
C o r n  o i l 5555 5
Lard - 10 10 10 10
AIN-mineral Mix
1) 3.5 3.5 3.5 3.5 3.5
AIN-vitamin Mix
2) 1.0 1.0 1.0 1.0 1.0
Choline chloride 0.2 0.2 0.2 0.2 0.2
Cranberry powder - - - 5 10
Cholesterol - 1.0 1.0 1.0 1.0
Sodium cholate - 0.5 0.5 0.5 0.5
NC, normal diet control group; HFC, atherogenic diet control group; HL, atherogenic 
diet and lipopolysaccharide (LPS) injected control group; HL-C5, atherogenic + 5% 
cranberry powder diet and LPS injected group; HL-C10, atherogenic + 10% cranberry 
powder  diet  and  LPS  injected  group
1) Composition  of  AIN-76  salt  mixture
2) Composition  of  AIN-76  vitamin  mixture
Table 1. Composition of the control and experimental diet (%) induced inflammation [15,16] for animals fed an atherogenic diet 
[16] to stimulate the early events of atherosclerosis. Then, we 
examined the effects of the freeze-dried cranberry powder on 
serum lipids, CRP and various inflammation-related cytokines 
as markers of cardiovascular disease risk and inflammation when 
rats were treated with an atherogenic diet and LPS. 
Materials and Methods
Animals and diet
Forty Sprague-Dawley male rats aged 6-weeks and weighing 
160-169 g were obtained from Animals Inc. (Central Lab., Seoul, 
South Korea) and kept under specific conditions in a temperature 
(23 ± 2℃) and humidity (50 ± 10%) controlled environment. 
After 7 days of acclimation, the animals were divided into five 
groups of similar mean body mass (Fig. 1); one group was provided 
a normal diet of 5% corn oil (control group, n = 8), two atherogenic 
diet groups were fed a diet containing 5% corn oil, 10% lard, 
1% cholesterol and 0.5% bile acid (HFC, n = 8; HL, n = 8), one 
group was fed the atherogenic diet with 5% added cranberry 
powder (HL-C5, n = 8), and one group was fed the atherogenic 
diet with 10% added cranberry powder (HL-C10, n = 8). 
Freeze-dried cranberry powder was purchased from Finlandia 
(Kiantama Oy Co., Suomussalmi, Finland) and all diet schemes 
were according to the modified AIN-76 [17] (Table 1). The 
experimental diets and water were provided ad libitum for 6 
weeks. The amount of food consumed was recorded every day, 
and the animals were weighed weekly.
The NC and HFC groups received 0.9% normal saline 
injections into the abdominal cavity 18 hours prior to sacrifice, 
and the HL, HL-C5, and HL-C10 groups had LPS (0.5 mg/kg 
LPS from Escherichia coli 026:B6, Sigma Co., St. Louis, MO, 
USA) injected into the abdominal cavity. The animals were 
sacrificed under ethyl ether anesthesia after a 12-hour fast. Liver 
and blood samples from the abdominal vein were collected into 
gel tubes containing coagulant for lipid profiling and biochemical 
analyses. All blood samples were immediately centrifuged 
(Sorvall ST16R Centrifuge, Thermo Scientific Co., Rockford, IL, 
USA) at 3000 rpm and 4℃ for 20 minutes to separate the serum, 
and stored at -75℃ before analysis.
Total phenolic and total flavonoid assay 
According to the method of Ainsworth and Gillespie [18], total 
soluble phenolic compounds were determined in cranberry 
powder with the Folin-Ciocalteu reagent using gallic acid as the 
standard. Distilled water (865 µl) and 50 µl of sample (100 mg 
freeze-dried cranberry powder in 1 ml distilled water) were 
incubated with 75 µl Folin-Ciocalteu reagent at room temperature 
for 5 min. Na2CO3 (225 µl of 20%) and 285 µl of distilled water 
were added to the reaction mixture, which was incubated at room 
temperature for 2 hours, and the absorbance was obtained at 760 
nm. Total phenolic content is expressed as gallic acid equivalent 
(GAE) in milligrams per gram of dried sample. 
The total flavonoid level in freeze-dried cranberry powder was 
measured by the method of Jia et al. [19]. Sample (500 µl total) 
was diluted with distilled water and 75 µl of 5% NaNO2 solution 
was added and incubated at room temperature for 5 min. This 
mixture was added to 150 µl of 10% AlCl3, and allowed to stand 
for a further 5 min before 0.5 ml of 1 M NaOH was added. 
The solution was measured at an absorbance of 510 nm. The 
results are presented as catechin equivalents in milligrams per 
gram of freeze-dried cranberry powder.406 Cranberry powder and inflammatory markers
Content
Total phenolic compound
(mg gallic acid equivalents/g) 18.17
Total flavonoid
(mg catechin equivalents/g) 7.33
1) Values are mean ± SD.
Table 2. Total phenolic compounds and total flavonoid levels in cranberry 
powder
1)
Group Food intake
(g/day)
Final body weight
(g)
Liver weight
(g)
Relative liver weight 
(g/100 g body weight)
NC 18.5 ± 0.8
a 375.9 ± 74.1
NS 13.1 ± 1.8
c 3.7 ± 1.5
b
HFC 15.2 ± 2.6
b 390.3 ± 53.5
  22.4 ± 3.8
b 5.7 ± 0.3
a
HL 16.6 ± 1.6
ab 411.4 ± 45.2
  25.4 ± 4.3
ab 6.2 ± 0.5
a
HL-C5 16.1 ± 1.7
b 407.7 ± 32.8
  25.9 ± 2.2
a 6.4 ± 0.3
a
HL-C10 17.2 ± 2.1
ab 398.9 ± 27.2
  25.0 ± 2.0
ab 6.3 ± 0.4
a
NC, normal diet control group; HFC, atherogenic diet control group; HL, atherogenic 
diet and LPS injected control group; HL-C5, atherogenic + 5% cranberry powder 
diet and LPS injected group; HL-C10, atherogenic + 10% cranberry powd er diet 
and  LPS  injected  group
n = 7-8/group
1) Values are mean ± SD, Means with different superscripts are significantly different 
at  P < 0.05  by  Duncan’s  multiple  range  test.
Table 3. Effects of cranberry powder on food intake, final body weight, liver 
weight, and relative liver weight in diet-induced and lipopolysaccharide (LPS)
injected hyperlipidemia rats
1)
Fig. 2. Change in body weights of the rats. Values  are  means.
Lipid profiles
Serum total cholesterol, HDL-cholesterol, and triglyceride 
levels were measured with an automatic biochemical analyzer 
(Vitalab Selectra E, Vital Scientific Co., Dieren, The Netherlands).
Serum CRP and TNF-α
Serum CRP levels were measured with an automatic biochemical 
analyzer (Vitalab Selectra E). 
Serum TNF-α levels were measured with a commercial kit (Rat 
TNF-α ELISA Kit, Invitrogen Co., Carlsbad, CA, USA) which 
employs a solid phase sandwich enzyme linked immunosorbent 
assay (ELISA) technique. Then, optical density was measured 
at 450 nm with a plate reader (Spectra max 250, Molecular 
Devices, Sunnyvale, CA, USA).
Serum IL-1β, IL-6, and IL-2
IL-1β and IL-6 contents were measured using corresponding 
commercial kits (IL-1β: Rat IL-1β ELISA kit, Thermo Scientific, 
IL-6: Rat IL-6 Immunoassay, R&D Systems Inc., Minneapolis, 
MN, USA), which employs sandwich ELISA techniques. Optical 
density values were measured at 450 nm using a plate reader.
IL-2 content was determined with a commercial ELISA kit 
(Rat IL-2 Immunoassay, R&D System). Optical density values 
were measured at 450 nm and 540 nm, and then the difference 
between the 450 nm reading and the 540 nm reading was used 
for analysis.
Serum IL-10 and NO
Serum IL-10 levels were measured with a commercial ELISA 
kit (Rat IL-10 ELISA Kit, Invitrogen), and optical density values 
were read on a plate reader at 450 nm. 
NO content was measured using the Griess Reagent System 
kit (Promega Co., Madison, WI, USA) which employs sulfani-
lamide and N-1-napthylethylenediamine dihydrochloride under 
acidic (phosphoric acid) conditions. The serum sample was 
reacted with the Griess Reagent for 10 minutes, and then 
absorbance was measured at 520 nm with a plate reader.
Statistical analysis
Statistics were conducted with SAS program version 9.1 (SAS 
Inc., Cary, NC, USA). Significant differences between groups 
were evaluated with a one-way analysis of variance and 
Duncan’s multiple range tests. Values are presented as mean ±
standard deviation, and P < 0.05 was considered statistically 
significant.
Results
Total phenolic compounds and total flavonoid levels
The levels of total phenolic and total flavonoid compounds 
in freeze-dried cranberry powder are shown in Table 2. The total 
phenolic compound level was 18.17 mg GAE/g, and the total 
flavonoid level was 7.33 mg catechin equivalents/g.
Body weights and food intake
Final body weights and food intakes are shown in Table 3, 
and changes in body weight are shown in Fig. 2. Mean weights 
increased gradually in all groups. Food intake in the HFC and 
HL-C5 groups decreased significantly and that of the other 
altherogenic diet groups (HL and HL-C10) tended to decrease Mi Joung Kim et al. 407
Group  Triglyceride 
(mg/dl)
Total cholesterol 
(mg/dl)
HDL- cholesterol 
(mg/dl)
NC 163.4 ± 97.0
a 98.5 ± 19.4
b 73.3 ± 13.4
a
HFC 63.6 ± 19.5
b 286.5 ± 45.9
a 44.9 ± 17.6
c
HL 96.7 ± 75.6
ab 251.7 ± 95.3
a 43.2 ± 9.0
c
HL-C5 123.6 ± 55.3
ab 330.5 ± 84.7
a 63.6 ± 8.7
ab
HL-C10 120.8 ± 49.8
ab 272.5 ± 93.3
a 54.9 ± 10.8
bc
NC, normal diet control group; HFC, atherogenic diet control group; HL, atherogenic 
diet and LPS injected control group; HL-C5, atherogenic +5% cranberry powder 
diet and LPS injected group; HL-C10, atherogenic + 10% cranberry p owd er diet 
and  LPS  injected  group
n = 7-8/group
1) Values are mean ± SD, Means with different superscripts are significantly different 
at  P < 0.05  by  Duncan’s  multiple  range  test.
Table 4. Effects of cranberry powder on serum lipid profiles in diet-induced and
lipopolysaccharide (LPS) injected hyperlipidemia rats
1)
Group CRP  (mg/l) TNF-α (pg/ml)
NC 15.3 ± 0.9
bc 15.2 ± 5.7
c
HFC 17.6 ± 2.2
a 46.8 ± 30.4
ab
HL 16.6 ± 1.9
ab 26.1 ± 14.7
bc
HL-C5 14.0 ± 1.3
c 70.3 ± 40.0
a
HL-C10 14.2 ± 2.2
c 57.1 ± 31.8
a
NC, normal diet control group; HFC, atherogenic diet control group; HL, atherogenic 
diet and LPS injected control group; HL-C5, atherogenic +5% cranberry powder 
diet and LPS injected group; HL-C10, atherogenic + 10% cranberry p owder d iet 
and LPS injected group; CRP, C-reactive protein; TNF-α, Tumor necrosis factor-alpha
n = 7-8/group
1) Values are mean ± SD, Means with different superscripts are significantly different 
at  P < 0.05  by  Duncan’s  multiple  range  test.
Table 5. Effects of cranberry powder on serum CRP and TNF-α levels in 
diet-induced and lipopolysaccharide (LPS) injected hyperlipidemia rat
1)
Group IL-1β (pg/ml) IL-6 (pg/ml) IL-2 (pg/ml)
NC 98.5 ± 16.8
a 75.8 ± 11.8
ab 19.7 ± 11.9
b
HFC 76.7 ± 26.5
ab 68.5 ± 11.0
b 18.6 ± 16.6
b
HL 90.4 ± 44.6
a 92.1 ± 21.6
a 22.8 ± 22.7
b
HL-C5 59.6 ± 9.3
bc 90.6 ± 10.9
a 59.3 ± 52.0
a
HL-C10 40.5 ± 20.0
c 84.1 ± 18.4
ab 26.9 ± 11.8
ab
NC, normal diet control group; HFC, atherogenic diet control group; HL, atherogenic 
diet and LPS injected control group; HL-C5, atherogenic +5% cranberry powder 
diet and LPS injected group; HL-C10: atherogenic + 10% cranberry p owd er diet 
and LPS injected group; IL-1β, Interleukin-1β; IL-6, Interleukin-6; IL-2, Interleukin-2
n = 7-8/group
1) Values are mean ± SD, Means with different superscripts are significantly different 
at  P < 0.05  by  Duncan’s  multiple  range  test.
Table 6. Effects of cranberry powder on serum IL-1β, IL-6 and IL-2 levels in
diet-induced and lipopolysaccharide (LPS) injected hyperlipidemia rat
1)
Group IL-10 (pg/ml) NO (pg/ml)
NC 23.0 ± 3.9
b 21.1 ± 6.6
 NS
HFC 27.1 ± 2.2
b 17.5 ± 2.7
HL 43.1 ± 27.0
ab 19.1 ± 7.5
HL-C5 55.4 ± 26.4
a 36.0 ± 9.7
HL-C10 64.4 ± 27.2
a 23.7 ± 5.6
NC, normal diet control group; HFC, atherogenic diet control group; HL, atherogenic 
diet and lipopolysaccharide (LPS) injected control group; HL-C5, atherogenic + 5% 
cranberry powder diet and LPS injected group; HL-C10, atherogenic + 10% cranberry 
powder  diet  and  LPS  injected  group;  IL-10,  Interleukin-10;  NO,  Nitric  oxide
n = 7-8/group
1) Values are mean ± SD, Means with different superscripts are significantly different 
at  P < 0.05  by  Duncan’s  multiple  range  test.
Table 7. Effects of cranberry powder on serum IL-10 and NO levels in 
diet-induced and lipopolysaccharide (LPS) injected hyperlipidemia rats
1)
when compared to food intake in the NC group. In addition, 
no significant changes were observed in the mean body weights 
of the groups regardless of altherogenic diet, LPS injection, or 
cranberry powder treatment. 
All atherogenic diet groups displayed a significant increase in 
liver weights and relative liver weights compared to those in 
the NC group. Compared to the HFC group, liver weights tended 
to increase in all groups injected with LPS (HL, HL-C5, and 
HL-C10) without significant differences (Table 3).
Lipid profiles
The effects of the cranberry powder on serum lipid profiles 
are summarized in Table 4. Average serum triglyceride level in 
the NC group was significantly higher than that in the HFC 
group, and there was a tendency for increased triglycerides in 
the LPS injected and cranberry powder treated groups. Serum 
total cholesterol levels in all atherogenic diet groups were 
significantly higher than those in NC group, but no significant 
changes were observed in the LPS injection or cranberry treated 
groups. HDL-cholesterol levels decreased significantly in rats fed 
the atherogenic diet, but increased with cranberry treatment. The 
HDL-cholesterol level of the HL-C5 group (63.6 mg/dl) was 
significantly higher than that of the HFC group (44.9 mg/dl) and 
HL group (43.2 mg/dl) but was not significantly different from 
the normal diet group (Table 4).
CRP and TNF-α
A significant increase in CRP levels was observed in the HFC 
group compared to those in the NC group. The cranberry diet 
groups (HL-C5: 14.0 mg/l, HL-C10: 14.2 mg/l) displayed a 
significant decrease in CRP levels compared to those in the HFC 
(17.6 mg/l) and HL groups (16.6 mg/l). The CRP levels in the 
cranberry diet groups were similar or tended to be lower than 
those measured in the NC group (Table 5). 
Serum TNF-α  level increased significantly in rats fed the 
atherogenic diet and cranberry treatment. The HFC group showed 
a significantly higher mean TNF-α (46.8 pg/ml) level compared 
to that in NC group (15.2 pg/ml). Additionally, both the HL-C5 
(70.3 pg/ml) and HL-C10 groups (57.1 pg/ml) had elevated TNF-
α compared to that in the HL group (26.1 pg/ml) (Table 5). 
Serum IL-1β, IL-6, and IL-2
Mean serum IL-1β level tended to decrease in rats fed the 
atherogenic diet, but was elevated by LPS injection. The 
cranberry diet groups (HL-C5 and HL-C10) displayed a 
significant decrease in IL-1β levels compared to those in the 
NC and HL groups (Table 6).
The IL-6 level in the HFC group was significantly lower than 
that in the LPS injected groups, particularly the HL and HL-C5 
groups. Cranberry treatment tended to produce lower IL-6 levels 408 Cranberry powder and inflammatory markers
TG CRP HDL T-CHO IL-1β IL-10 TNF-α IL-2 IL-6
CRP -0.327*
HDL 0.502** -0.499**
T-CHO -0.008 -0.138 -0.323*
IL-1β 0.152 0.206 0.008 -0.176
IL-10 0.100 -0.370* -0.146 0.409* -0.232
TNF-α -0.005 -0.269 -0.083 0.479** -0.345* 0.606***
IL-2 -0.083 -0.145 -0.038 0.087 -0.179 0.286 0.434**
IL-6 0.156 -0.143 0.163 0.127 0.140 0.172 -0.130 0.087
NO 0.638*** -0.328* 0.222 0.550*** 0.117 0.249 0.247 0.014 0.178
TG, Triglyceride; CRP, c-reactive protein; HDL, HDL-cholesterol; T-CHO, Total cholesterol; IL-1β, Interleukin-1β; IL-10, Interleukin-10; TNF-α: Tumor necrosis factor-α; IL-2, 
Interleukin-2;  IL-6,  Interleukin-6;  NO,  Nitric  oxide
Significantly  correlated  between  measures  at  *P < 0.05,  **P < 0.01,  ***P < 0.001  by  partial  correlation  coefficient.
Table 8. Correlation coefficients among serum lipids and inflammatory markers in diet-induced and lipopolysaccharide (LPS) injected hyperlipidemia rats
(Table 6).
Mean IL-2 level tended to increase following the LPS injection 
and significantly increased with the 5% cranberry treatment. The 
mean IL-2 level in the HL-C5 group was significantly higher 
than that in the NC, HFC, and HL groups (Table 6).
Serum IL-10 and NO 
The mean IL-10 levels in the cranberry diet groups (HL-C5 
and HL-C10) were significantly higher than those in the NC and 
HFC groups. Cranberry treatment tended to increase serum IL-10 
levels, but this did not reach significance (Table 7).
Serum NO and IL-10 levels are involved in atherosclerosis 
through the effect on endothelium-dependent vasodilation, and 
were measured as an indicator of this effect. Although no 
significant difference was observed between the groups, the 
cranberry treated groups (HL-C5 and HL-C10) displayed 88 and 
24% increases in NO levels.
Correlation among serum lipids and inflammatory markers
HDL was significantly negatively correlated with serum CRP 
and total cholesterol. CRP was also negatively correlated with 
IL-10 and NO levels. Serum TNF-α was significantly positively 
correlated with total cholesterol, IL-10, and IL-2, but negatively 
correlated with IL-1β. Additionally, NO was positively correlated 
with triglycerides and total cholesterol (Table 8).
Discussion
This study was conducted to determine the anti-inflammatory 
and ameliorative effects of freeze-dried cranberry powder on 
cardiovascular diseases in relation to the inflammatory system. 
We investigated serum lipid profiles, CRP, and markers of the 
inflammatory response related to cardiovascular disease risk in 
rats fed an atherogenic diet with inflammation-induced by an 
LPS injection. 
Cranberry, one of the flavonoid and polyphenol rich fruits, has 
beneficial health effects on cancers and vascular diseases [13]. 
Vinson et al. [14] reported that the average total phenol content 
was 870 mg/100 g dried cranberries, and it was highest in the 
freeze-dried product among the fruits tested such as apricots, figs, 
grapes, raisins, and dried plums. In our previous study, total 
flavonoid content of freeze-dried cranberry powder was 8.2 mg 
catechin equivalents/g and total phenolic content was 9.94 mg 
GAE/g [8]. The freeze dried cranberry powder used in the current 
study contained about twice the total phenolics than we used 
in our previous study [8], suggesting that freeze-dried cranberry 
powder is certainly high in phenolics but that total phenolic 
content may vary due to the manufacturing process, cranberry 
type, or maturation stages. 
Ryu and Cha [20] have demonstrated that increased carbohydrates 
in the diet may raise serum triglycerides due to synthesis of 
hepatic triglycerides. The normal diet used in the current study 
had a relatively higher composition of carbohydrates than that 
in the atherogenic diet, and the average food intake in the NC 
group was significantly higher than that in the other groups. 
These dietary differences might partially explain the reason why 
we observed a significantly higher serum triglyceride level in 
the NC group. In addition, as Uchiumi et al. [21] reported that 
LPS increases serum triglycerides, we also observed a slight 
elevation in serum triglycerides following the LPS injection. 
However, we failed to observe the hypolipidemic effect of 
cranberry powder. Cranberry improves dyslipidemia in animals 
and human [2,22]. Ruel et al. [22] reported that cranberry 
consumption in men resulted in an increase in HDL-cholesterol 
but no change in total cholesterol. In contrast, Reed [2] reported 
that cranberry juice powder has the potential to decrease blood 
total cholesterol levels in an atherosclerotic animal model. 
Kalgaonkar  et al. [23] suggested that total cholesterol, LDL- 
cholesterol, and LDL oxidation decreased by consuming large 
amounts of cranberries. Ruel et al. [22] demonstrated increased 
HDL-cholesterol levels in overweight men after 12 weeks of 
low-calorie cranberry juice consumption. However, our previous 
study [8] demonstrated no significant changes in both triglyceride 
and total cholesterol levels in rats treated with freeze-dried 
cranberry powder, whereas HDL-cholesterol levels increased Mi Joung Kim et al. 409
significantly with 5% cranberry supplementation. The current 
study showed similar results regarding the effect of cranberry 
on serum lipids. The 5% cranberry powder supplementation 
resulted in a significant increase in HDL-cholesterol levels 
compared to those in the HL group. Additionally, 10% cranberry 
powder supplementation displayed a trend towards an increase. 
According to the study by Ridker [24], CRP is regarded as 
an inflammatory indicator and a potential risk factor for 
cardiovascular disease. CRP facilitates atherosclerosis through 
influences on vascular cell activation, monocyte recruitment, 
lipid accumulation, and blood clot formation [25]. Other studies 
have reported that CRP is an independent risk factor for 
atherosclerosis, cardiovascular events, and myocardial infarction 
[26,27]. In the current study, serum CRP levels were significantly 
elevated in rats on the atherogenic diet for 6 weeks. However, 
when freeze-dried cranberry powder was added to the diet, the 
increased CRP decreased significantly to a level even lower than 
that in rats fed the normal diet. In a population based study, 
total flavonoid intake was significantly negatively correlated with 
serum CRP levels in US adults [28]. Chun et al. [28] suggested 
that flavonoids might inhibit the synthesis and expression of 
NF-kB, which can influence CRP production as an upstream 
regulator of pro-inflammatory cytokines synthesis. This might 
partially explain the effect of flavonoid-rich cranberry on 
lowering CRP. We observed a significant negative correlation 
between CRP and HDL-cholesterol. Fröhlich et al. [29] also 
reported a negative correlation between CRP and HDL-cholesterol 
in a population based study. It has been suggested that HDL 
is a potential anti-inflammatory particle because of the anti- 
inflammatory effect of Apo A1, which is a major HDL protein 
[12]. 
IL-1β  and IL-6, inflammation-mediatory cytokines, play 
important roles in vascular inflammation and progression of 
atherosclerosis [30]. IL-1β  induces necrosis and infection by 
causing damage to blood vessels [31], and IL-6 is a potent 
stimulant of CRP generation in the liver [32]. Huang et al. [6] 
reported a significant decrease in LPS-induced IL-1β production 
in human peripheral blood mononuclear cells after treatment with 
cranberry extract. Bodet et al. [33] mentioned that macrophage 
production of pro-inflammatory cytokines including IL-1β and 
IL-6 are inhibited by the highly concentrated proanthocyanidin 
fraction of a cranberry extract. Our results showed that serum 
IL-1β and IL-6 levels increased following an LPS injection and 
decreased with cranberry powder treatment, particularly the 10% 
cranberry powder supplement. Reed [2] and Park et al. [34] 
suggested that flavonoids inhibit the production of inflammatory 
cytokines such as IL-6 and IL-1β by acting as gene expression 
inhibitors and the production of pro-inflammatory cytokines by 
suppressing activation of transcription factors such as NF-kB and 
NF-kB/DNA binding. TNF-α  is an indicator of the systemic 
inflammatory response related to atherosclerosis and cause the 
expression of endothelial cell adhesion factors [35]. In human 
studies, serum TNF-α level increases in patients with coronary 
artery disease and secretion of TNF-α by mononuclear leukocytes 
increases in patients with ischemic heart disease [36]. Additionally, 
Bodet et al. [33] reported decreased TNF-α secretion by LPS- 
induced macrophages following treatment with a high-molecular- 
weight cranberry fraction from cranberry juice, which contained 
mainly anthocyanins and proanthocyanidins at levels 125 times 
higher than those in freeze-dried cranberry juice. Bodet et al. 
[33] assumed that the effects were due to concentration of active 
compounds including proanthocyanidins in the high-molecular- 
weight cranberry fraction. In contrast, TNF-α production in LPS- 
stimulated human leukemia cells increases when cells are treated 
with a cranberry polyphenol fraction, although NF-kB activation 
is down-regulated by cranberry polyphenols [37]. Similarly, we 
observed noticeable elevations in serum TNF-α levels in the 
groups fed cranberry, suggesting that TNF-α expression may be 
up-regulated by alternate pathway other than NF-kB [38]. 
IL-2 may promote expansion and activation of Th1 cells, 
causing plaque development, which is believed to actively 
promote atherogenesis [39]. Nabata et al. [40] suggested that IL-2 
is related to the pathogenesis of atherosclerosis and vascular 
disease by modulating the response to angiotensin II. Procyanidins, 
abundant in cranberry and chocolate, inhibit IL-2 expression and 
modulate IL-2 production in cells [41]. However, in the current 
study, we failed to define any noticeable modulatory effect of 
cranberry powder on IL-2 levels.
IL-10 is a well known anti-inflammatory cytokine, which has 
anti-atherogenic and anti-apoptotic properties [42]. While IL-10 
production is increased by polyphenols [43], IL-10 is regulated 
by the production of pro-inflammatory cytokines such as IL-1β, 
IL-6, and TNF-α in infection or tissue damage [44]. In the current 
study, we found a significant positive correlation between IL-10 
and TNF-α. In addition, Lakoski et al. [45] reported that elevated 
IL-10 level is related with a risk for cardiovascular heart disease 
events and suggested that IL-10 might increase by the response 
to the pro-inflammatory environment of atherosclerosis. In a 
study by Deitschel et al. [46], IL-10 production was stimulated 
by LPS treatment in dogs. Similarly, we observed a tendency 
for increasing IL-10 levels in the LPS injected group compared 
to those in the non-LPS injected group. While we assumed that 
this increase was a response to the induction of an inflammatory 
reaction to LPS, there were further enhancements of IL-10 levels 
observed in rats fed the cranberry powder supplement. These 
results suggest that IL-10 production might be boosted by 
cranberry powder treatment during the inflammatory reaction 
induced by LPS. Similarly, Svajger et al. [43] demonstrated that 
the polyphenol resveratrol increases IL-10 production from LPS- 
treated dendritic cells. However, the mechanism of IL-10 
increasing effect of polyphenols or polyphenol rich food products 
needs to be further elucidated.
NO plays an important role in vascular endothelial cell 
function. It inhibits a rise in blood pressure and has a vasodilatory 
effect [47]. NO is produced by the enzyme nitrogen oxide 
synthase (NOS) acting on L-arginine, and acts as an antioxidant 410 Cranberry powder and inflammatory markers
via diffusion. NO protects LDL against oxidation, inhibits platelet 
aggregation, and decreases endothelial adhesion of leukocytes 
[23]. However, Huang et al. [6] reported no significant effect 
of cranberry extract on the activity of NOS in vivo. In contrast, 
we found that cranberry powder fortified groups showed an 
increasing trend in NO levels, although it did not reach 
significance. Similarly, proanthocyanins have been demonstrated 
to increase endothelial NO production and improve vasodilation 
in an in vitro experiment [48]. Maher et al. [49] reported that 
phenolics from cranberry juice have an NO-dependent vasodilation 
and blood pressure decreasing effect in rats, suggesting that NO 
might have potential roles as an antioxidant or vasodilator in 
vascular endothelial cells helping to stabilize cardiovascular 
diseases. 
In summary, when 5 or 10% cranberry powder was supple-
mented with a high fat diet, LPS-treated rats seemed to achieve 
some anti-inflammatory effects by reducing serum CRP, IL-1β 
and IL-6, and enhancing IL-10 in dose-dependent manner. 
Similar to previous reports, consuming cranberry products might 
also have potential cardiovascular benefits possibly by modifying 
serum lipids and biomarkers of inflammation [11,12,22,33]. 
However, we observed an increased TNF-α level when cranberry 
powder was supplemented with the diet. Additionally, there is 
no consensus among studies for the effect of cranberry on TNF-α 
production [33,37]. Therefore, various bioactive components of 
cranberry need to be classified and tested to better understand 
the function of cranberry as an inflammation regulator. Further-
more, transcriptional mechanisms of action for the cranberry 
flavonoids should be verified in relation to their function of 
modifying biomarkers of inflammation. 
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